Cost-effectiveness of ranibizumab versus aflibercept in the treatment of visual impairment due to diabetic macular edema: a UK healthcare perspective

Cost-effectiveness of ranibizumab versus aflibercept in the treatment of visual impairment due to diabetic macular edema: a UK healthcare perspective

Stephane A Régnier,1 William Malcolm,2 Jennifer Haig,3 Weiguang Xue41Novartis Pharma AG, Basel, Switzerland; 2Novartis Pharmaceuticals UK Ltd, Frimley Business Park, UK; 3Optum, Burlington, ON, Canada; 4Optum, Uxbridge, UKBackground: Ranibizumab and aflibercept are alternative anti-vascul...

Full description

Bibliographic Details
Main Authors: Régnier SA, Malcolm W, Haig J, Xue W
Format: Article
Language:English
Published: Dove Medical Press 2015-05-01
Series:ClinicoEconomics and Outcomes Research
Online Access:http://www.dovepress.com/cost-effectiveness-of-ranibizumab-versus-aflibercept-in-the-treatment--peer-reviewed-article-CEOR

Internet

http://www.dovepress.com/cost-effectiveness-of-ranibizumab-versus-aflibercept-in-the-treatment--peer-reviewed-article-CEOR

Similar Items